PDCD1 and extranodal nasal NK/T cell lymphoma: In a study of 9 patients with advanced NKTCL [59], PD-1 inhibitors in combination with P-GemOx chemotherapy demonstrated 88.9% ORR, 77.8% CR rate, 66.7% 1-year PFS rate and 100.0% 1-year OS rate.